The Global Comprehensive Metabolic Panel (CMP) Testing Market size is expected to reach over US$ 18,380 Mn by 2026 and growing at a CAGR of around 7.0% from 2019 to 2026.
The Comprehensive Metabolic Panel (CMP) is a commonly ordered set of 14 tests that give doctor a significant data about the present status of kidneys, electrolyte, liver and acid / base balance as well as blood sugar and blood proteins. Abnormal findings, and in particular abnormal results combinations, may show an issue that needs to be resolved. The CMP is used as a wide screening instrument for diabetes, liver illness, and kidney disease conditions. It is also used for monitoring disease complications or side effects of drugs used for disease treatment. The CMP is regularly provided for a medical or annual physical examination as part of a blood work-up and is gathered by inserting a needle into arm's vein.
Healthcare awareness among consumers is one of the major factors expected to drive the CMP testing market. Many organizations around the globe are working to increase awareness of illnesses, treatment choices available, and early diagnosis and precautions advantages. The International Diabetes Foundation and the American Diabetes Association, for example, are some of the main organizations that emphasize the pressing need to diagnose and monitor diabetes through multiple awareness campaigns and other advertising methods. Furthermore, over the past few years, the landscape of medical diagnostics has experienced a fundamental shift, driven by the launch of enhanced diagnostic products and biomarker introduction. Recurrence and progression of disease, however, stay high, particularly among geriatric patients. Strong unmet demands pose a main chance in the CMP testing room to create first-class breakthrough diagnostics.
Above pie chart represents the global market share of comprehensive metabolic panel (CMP) testing market, by disease in 2018. The comprehensive metabolic panel market is segmented into disease, test type, end-use and region. The disease segment is bifurcated into kidney disease, liver disease, diabetes, and others. Kidney disease holds near about 42% share of comprehensive metabolic panel (CMP) testing market due to the rising incidence of kidney disease, increasing the amount of biopsy processes and growing demand for fresh chronic disease diagnostic methods. In addition, the accessibility of multiple kidney disease diagnostic tests also affects market growth. It is also anticipated that the growing number of market players will boost market growth during the forecast period. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has indicated that kidney disease is often referred to as a "silent disease" as there are no symptoms in its early phases and may remain undetected.
The market research study on “Comprehensive Metabolic Panel (CMP) Testing Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026, offers a detailed insights on the global comprehensive metabolic panel (CMP) testing market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report provides insights on global comprehensive metabolic panel (CMP) testing market, its product, power source, application, and major geographic regions. The report covers basic development policies and layouts of technology development processes. The comprehensive metabolic panel (CMP) testing market analysis is provided for major regional markets including North America, Europe, Asia-Pacific, Latin America, Middle East & Africa followed by major countries. For each region, the market size for different segments has been covered under the scope of report. The North America includes the global kidney disease market's highest share. The regional market stupendous performance is the consequence of increasing renal disease incidence, especially among geriatric population. In addition, in latest years, the availability of advanced healthcare services in the region has brought great revenue. Regional businesses also stress the need for more studies and development (R&D) and fresh goods to be developed. The growth in financing will also complement these factors, which will assist the region retain its top place throughout the assessment period. Europe has shown optimistic development, supported by high healthcare expenditure and increased awareness of kidney diseases. In addition, increasing public suggestions for CMP and rapidly increasing geriatric population are set to further elevate the market situation in this region. During the forecast period, Asia Pacific is anticipated to grow at the largest CAGR, driven by improved healthcare infrastructure, increased customer awareness, increased disposable income, and general economic development. The market is anticipated to experience fast development in demand for CMP testing in emerging countries such as China, India, and South Korea over the forecast period. The Middle East & Africa is increasing at a steady pace as the incidence of kidney diseases in the region has increased over the previous few years and is also anticipated to increase during forecast period.
The players profiled in the report are Sonic Healthcare, Quest Diagnostics, UNIPATH, Laboratory Corporation of America Holdings (LabCorp), Abbott, SYNLAB International GmbH and among others. The company operated in the market will increase their footprint in the global market by merger and acquisition of local players and focus on the research & development for advance technology.
Market By Disease
Market By Test Type
Market By End-Use
Market By Geography